anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People between the ages of 18-65, diagnosed with Carpal Tunnel Sedrome, who are suitable for the Nosiplastic pain phenotype and who volunteer to participate in the study will be included. The 7 steps in the Clinical Criteria/Rating System determined by the International Association for the Study of Pain (IASP) for Nosiplastic Pain will be applied to patients with CTS. After determining the predominant pain phenotype in patients with CTS, patients with mixed type (neuropathic and nosiplastic pain phenotype) will be randomly divided into two groups. One group (Group 1) will receive desensitisation and the other group (Group 2) will receive desensitisation and pain neuroscience education. Numerical rating scale (NRS) will be used for pain assessment. Boston Carpal Tunnel Questionnaire - Symptom Severity Scale will be used for symptom severity assessment and Boston Carpal Tunnel Questionnaire - Functional Status Scale will be used for functional status assessment. Pressure pain threshold will be measured with an algometer to evaluate hypersensitivity. The Pain Catastrophising Scale and the Tampa Kinesiophobia Scale will be administered to the patients. Normality of the data distribution will be assessed using the Shapiro-Wilk test. Fischer's exact test and chi-square test will be used to verify the relationship between categorical variables. A mixed model ANOVA will be performed on 2 (group 1 and group 2) x 3 (time: baseline, post-intervention, 3 months post-intervention) different outcome measures (pain intensity, symptom severity, functional status, pain catastrophising and kinesiophobia) to detect between-group differences.
The invention provides a cimetidine composition freeze-drying tablet and a preparation method thereof and relates to the technical field of medicines and medicine production. The cimetidine composition freeze-drying tablet comprises cimetidine, starch and cane sugar, wherein starch and cane sugar are used as auxiliary materials, and common corn starch is treated by virtue of a heating process, so that the bonding and disintegrating effects of starch in a tablet can be improved and the formability of the tablet is improved. The cimetidine composition freeze-drying tablet just needs two auxiliary materials, namely starch and cane sugar. According to the cimetidine composition freeze-drying tablet, a freeze-drying process of reducing the temperature twice and raising the temperature twice is adopted, so that the tablet formability is better and the dissolution rate of the tablet is improved, and therefore, the bioavailability of the tablet is improved. The tablet overcomes the defects of common cimetidine tablet, and the type and dosage of the auxiliary materials in the cimetidine tablet are reduced. The tablet is great in dissolution rate and high in bioavailability, and the curative effect and safety of clinical medication are guaranteed.
Patients who undergone ASCT and received CART cell infusion sequently within 1 month. Patients with disease recurrence or progression prior to the infusion of CART cells will be excluded.
A composition (I) including garlic, garlic extract or derivatives in combination with emu oil and a pharmaceutically or veterinary acceptable carrier. Independent claims are also included for a method of treatment and/or prophylaxis of skin disorders by the therapeutic administration of the composition (I) and the use of a combination of garlic extracts or derivatives with emu oil in the manufacture of a medicament for the treatment and/or prophylaxis of skin disorders. ACTIVITY : Antiinflammatory; dermatological; antifungal; viricide. An elderly woman had been suffering with tinea for many years and in recent months it had spread from her toes to her feet and half way up her knees. A composition containing sorbolene (92 wt. %), kyolic (5 wt. %) and Unigerm G2 (RTM) (3 wt. %) was applied to the tinea twice a day. The tinea stopped itching almost immediately. After 2 - 3 days it started healing and within 10 days the tinea had completely disappeared. MECHANISM OF ACTION : None given.
Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
Tizanidine is closely related to clonidine, which is often abused in combination with narcotics and is known to cause symptoms of rebound upon abrupt withdrawal. Three cases of rebound symptoms on sudden withdrawal of tizanidine have been reported. The case reports suggest that these patients were also misusing narcotics. Withdrawal symptoms included hypertension, tachycardia, hypertonia, tremor, and anxiety. Withdrawal symptoms are more likely to occur in cases where high doses are used, especially for prolonged periods, or with concomitant use of narcotics. If therapy needs to be discontinued, the dose should be decreased slowly to minimize the risk of withdrawal symptoms [see Dosage and Administration (2.2)].

Monkeys were shown to self-administer tizanidine in a dose-dependent manner, and abrupt cessation of tizanidine produced transient signs of withdrawal at doses > 35 times the maximum recommended human dose on a mg/m2 basis. These transient withdrawal signs (increased locomotion, body twitching, and aversive behavior toward the observer) were not reversed by naloxone administration.
Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
In the era of high throughput sequencing, special software is required for the clinical evaluation of genetic variants. We developed REEV (Review, Evaluate and Explain Variants), a user-friendly platform for clinicians and researchers in the field of rare disease genetics. Supporting data was aggregated from public data sources. We compared REEV with seven other tools for clinical variant evaluation. REEV (semi-)automatically fills individual ACMG criteria facilitating variant interpretation. REEV can store disease and phenotype data related to a case to use these for phenotype similarity measures. Users can create public permanent links for individual variants that can be saved as browser bookmarks and shared. REEV may help in the fast diagnostic assessment of genetic variants in a clinical as well as in a research context. REEV (https://reev.bihealth.org/) is free and open to all users and there is no login requirement.
Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
Geriatric (age \>65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
[Problem] To promote the expression of a clock gene and a hyaluronic acid synthase gene in the skin more effectively. [Solution] A composition comprising one or both of a lavender oil and a eucalyptus oil and an alkylene oxide derivative represented by general formula (I) is applied to the skin. (In the formula, AO represents an oxyalkylene group having 3-4 carbon atoms; EO represents an oxyethylene group; m and n independently represent the average number of moles of the oxyalkylene groups each having 3-4 carbon atoms added and the average number of moles of the oxyethylene groups added, respectively, wherein 1 ≤ m ≤ 70 and 1 ≤ n ≤ 70; wherein the ratio of the content of the oxyethylene group is 20-80 mass% relative to the total content of the oxyalkylene group and the oxyethylene group. The oxyalkylene group and the oxyethylene group are added in the form of a block or randomly. R 1  and R 2  may be the same as or different from each other, and independently represent a hydrocarbon group having 1-4 carbon atoms or a hydrogen atom, wherein the ratio of the number of hydrogen atoms relative to the number of hydrocarbon atoms in R 1  and R 2  is 0.15 or less. R 1 -[(AO) m (EO) n ]-R 2  (I)
Over 60 million Americans use herbal medicines; of these, one-fourth also take prescription drugs. Physicians are often unaware of herbal use and of possible drug/herb interactions in their patients. Ginseng and ginkgo, enhancers of physical and mental performance, are two of the most widely taken herbals. We propose a double-blind, randomized, prospective study of effects of ginseng and ginkgo on 1) disposition of probe drugs, 2) cognitive function, and 3) glutathione-S-transferase (GST) and quinone reductase (NQ01), enzymes implicated in chemoprevention of cancer. Probe drugs will be administered to study effects of herbs on their disposition, not for therapeutic effect. Ideal probes must be safe, well tolerated, have minimal pharmacological effect, and share known metabolic pathways with other clinically used drugs. Medically stable drug-free non-smokers will be enrolled.

During a 4-week single-blind run-in, subjects will be given a 4-drug probe cocktail: caffeine to study cytochrome P4501A2 (CYP1A2), dextromethorphan for CYP2D6, buspirone (and endogenous cortisol) for CHP3A and fexofenadine for P-glycoprotein. Losartan will be given separately for CYP2C9. These enzymes metabolize over 95% of clinically used drugs. Enzyme activities will be determined by assaying appropriate blood and urine specimens for probe drugs and metabolites. Cognitive function will be tested and blood lymphocytes collected for measuring GST and NQ01 activities. Sixty subjects will then be randomly assigned to one of 4 double-blind treatment groups of 15 each: 1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos. Tolerability of herbs will be determined. After 6 to 8 weeks of twice daily treatment with study agents, all effect parameters will be reevaluated: probe drug pharmacokinetics, cognitive function, and GST and NQ01 in blood lymphocytes. Interactions of chronic ginseng and ginkgo with drug-metabolizing pathways and with cognitive function will thus be determined.
Patients will undergo treatment with a combination of BPI-1178 capsules and osimertinib tablets. Patients will orally receive a single dose of BPI-1178 (200 or 300 mg) capsules and osimertinib tablets (80 mg). After a 7-day washout period, continuous dosing will commence on the 8th day. During the continuous dosing phase, BPI-1178 capsules and osimertinib tablets will be administered once daily, with a treatment cycle consisting of 28 days.
Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia. Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued.

Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in manic-depressive patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy have not been established.

When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine product for enhancing immunity and a preparation method thereof. The traditional Chinese medicine product comprises the following raw materials in percentage by weight: 60-70% of main drug, 20-35% of auxiliary material and 4-10% of flavoring agent; the main drug is ganoderma lucidum mycelium powder. The traditional Chinese medicine product selects ganoderma lucidum mycelia as a main material, can greatly shorten the culture and growth period, has low energy consumption and stable yield and can realize rapid large-scale production compared with the similar products which take ganoderma lucidum sporocarp or spore as a raw material and are mainstream in the market at present. The process route of the traditional Chinese medicine product is simple and clear, not only can remove impurity components, but also can reserve effective components to the maximum extent, meets the production requirements of domestic enterprises at present, and has lower cost. The used raw and auxiliary materials have no pollution to the environment. The traditional Chinese medicine product disclosed by the invention is economical in cost, has no toxic or side effect, has the effect of enhancing the immunity of a human body, and is one of ways for effectively improving the public immunity through food therapy.
The invention discloses vitality strengthening tea which is prepared from the following components in parts by weight: 9-10 parts of astragalus, 4-5 parts of ginsengs, 4-5 parts of bighead atractylodes rhizome, 3-4 parts of pericarpium citri reticulatae, 6-7 parts of radix ophiopogonis and 1-2 parts of raw liquorice. The invention further discloses a preparation method of the vitality strengthening tea beverage. The vitality strengthening tea disclosed by the invention is reasonable in formula and safe and reliable. Components of a prescription are improved and optimized after long-term systematic research on a qi-tonifying soup formula. By adopting the latest manufacturing technology of a scientific process, a medicinal and edible life-preserving health-care tea beverage is finished, has the effects of nourishing and strengthening and is suitable for people with poor functions of spleen and stomach and deficiency of both qi and yin. The vitality strengthening tea serves as a comprehensive anti-fatigue odd-ingredient prescription, efficacious prescription and proved prescription for preventing and treating chronic fatigue.
12.1 How Supplied

Trubrexa TM Transdermal Patch comes in a sealed pouch bag. Each patch is 2 in x 2 in (5.08 cm x 5.08 cm) and consists of an adhesive side containing the active/inactive ingredients and an outer surface backing layer. The adhesive side is covered with a removable, clear, unprinted, plastic film. The outer surface of the backing layer is imprinted with the Trubrexa TM Transdermal Patch logo. 

Trubrexa TM Transdermal Patch is available as a unit box containing 32 patches (8 pouch bags). NDC 83295-4000-1 

12.2 Storage

Store unit box between 68 o-77 o F (20 o-25 o C). Excursions between 15 o-30 o C (59 o-86 o F) are allowed. Keep Trubrexa TM Transdermal Patch in the sealed pouch bags until immediately before use. 

12.3 Handling and Disposal

Unintended exposure to capsaicin can cause severe irritation of eyes, skin, respiratory tract, and mucous membranes. Avoid contact with your eyes, nose, or mouth. Keep used and unused patches out of the reach of children and pets. Pouch bags are not child resistant. Wash hands with soap and water after handling the patch. If irritation or a burning sensation occurs during application, remove the patch and do not reapply until the irritation subsides. After use, fold patches so that the adhesive side sticks to itself, then safely discard used patches where children and pets cannot get to them.
Patients to be included in the study will be selected from the group between the ages of 18 and 70 who apply to general surgery and emergency outpatient clinics, depending on patient approval. All patients will be informed about the surgery and procedures to be performed. Patients who agree to participate in the study will be included in the study. The study will be carried out by 2 surgeons with 5 years of laparoscopic cholecystectomy (LC) experience. Adult patients presenting with acute cholecystitis who underwent emergency LC by one of the two surgeons will be included in the study. These two surgeons will be responsible for participant registration. Patients with fever greater than 3.37.2 ℃, including 1) a diagnosis of acute cholecystitis confirmed by hepatobiliary ultrasound, 2) a high leukocyte count (\> 7 × 109 / L), will be included in the study. Patients undergoing elective laparoscopic cholecystectomy (E-LC) and patients who are converted to an open procedure will be excluded from the study. Patients will be divided into two groups. In Group A, patients with emergency LC will be administered intravenously 1 gr vial of paracetemol in 30 minutes during the awakening phase. In Group B, the lateral part of the latissumus dorsi muscle attaches to the external lip of the iliac crest, behind the middle axillary line and the end is directed towards the cranial, firstly the external oblique muscle and fascia, then the internal oblique muscle and fascia, and after hydrodissection with saline physiological. 15-20 ml of local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally.

Standard laparoscopic cholecystectomy will be applied in two groups. Nasogastric tube will be inserted after intubation in both groups and will be removed at the end of the operation. Age, height, weight, ASA score, body mass index, duration of surgery, complications, comorbidities, fever, leukocyte, CRP levels, ALT, AST, GGT, total bilirubin, direct bilirubin values will be recorded. Pulse, heart rate, systolic and diastolic pressures, Oxygen saturation (with a palimeter) will be recorded during surgery in both groups. VAS and VRS pain scoring will be done after surgery. VAS (Visuale analogue score) 0-10 cm and VRS (no pain in cough (score = 0); pain in cough, not in deep breathing (score = 1); pain in deep breathing, but not at rest (score = 2); at rest pain will be evaluated as mild (score = 3); pain at rest, severe (score = 4)). Evaluations will be made statistically between the two groups.
Fractionated stereotactic radiotherapy (fSRT) will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered every other day (\~2 times/week) with first cycle of Durvalumab.
PURPOSE: A ligament reconstruction method that simultaneously tensions the medial and lateral sides of the elbow and maintains tension with compression plates on the proximal ulna is proposed for the treatment of bidirectional elbow ligament instability. Graft slippage, catastrophic failure, and excessive displacement were evaluated. Biomechanical stability without graft slippage was hypothesized.
METHODS: Eight cadaveric ligament reconstruction simulations were created through the dissection of three cadaver arms. Each reconstruction was statically tested with 160 N in a manner where it was first augmented with an absorbable suture and then without. Then, 3 more ligament reconstruction simulations were created for dynamic testing with each undergoing testing at 80 N for 2,000 cycles at 2 Hz. Construct displacement and graft slippage were recorded for each load application.
RESULTS: No grafts failed catastrophically and no graft slippage was observed with either static or dynamic loading. Under static loading, the mean change in displacement between augmented and nonaugmented ligament reconstruction simulations was 28.7% ± 21% (augmented 3.95 ± 1.81 mm vs nonaugmented 4.89 ± 2.22 mm). The mean stiffness was 66.6 ± 26.6 N/mm for augmented and 64.6 ± 23.2 N/mm for nonaugmented simulations. With dynamic loading, the mean displacement for augmented graft ligament reconstruction simulations was 1.55 ± 0.16 mm compared with 2.18 ± 0.77 mm for nonaugmented reconstruction simulations.
CONCLUSIONS: This method of fixation to the proximal ulna for the simultaneous reconstruction of medial and lateral elbow ligaments successfully prevented graft slippage without excessive construct displacement during static and dynamic testing. Ligament augmentation with absorbable sutures decreased the construct displacement.
CLINICAL RELEVANCE: This ligament fixation method may be a viable alternative for the treatment of concomitant medial and lateral elbow instability.
PURPOSE: The benefit of endovascular treatment (EVT) in patients with acute symptomatic isolated occlusion of the internal carotid artery (ICA) without involvement of the middle and anterior cerebral arteries is unclear. We aimed to compare clinical and safety outcomes of best medical treatment (BMT) versus EVT + BMT in patients with stroke due to isolated ICA occlusion.
METHODS: We conducted a retrospective multicenter study involving patients with isolated ICA occlusion between January 2016 and December 2020. We stratified patients by BMT versus EVT and matched the groups using propensity score matching (PSM). We assessed the effect of treatment strategy on favorable outcome (modified Rankin scale ≤ 2) 90 days after treatment and compared reduction in NIHSS score at discharge, rates of symptomatic intracranial hemorrhage (sICH) and 3‑month mortality.
RESULTS: In total, we included 149 patients with isolated ICA occlusion. To address imbalances, we matched 45 patients from each group using PSM. The rate of favorable outcomes at 90 days was 56% for EVT and 38% for BMT (odds ratio, OR 1.89, 95% confidence interval, CI 0.84-4.24; p = 0.12). Patients treated with EVT showed a median reduction in NIHSS score at discharge of 6 points compared to 1 point for BMT patients (p = 0.02). Rates of symptomatic intracranial hemorrhage (7% vs. 4%; p = 0.66) and 3‑month mortality (11% vs. 13%; p = 0.74) did not differ between treatment groups. Periprocedural complications of EVT with early neurological deterioration occurred in 7% of cases.
CONCLUSION: Although the benefit on functional outcome did not reach statistical significance, the results for NIHSS score improvement, and safety support the use of EVT in patients with stroke due to isolated ICA occlusion.
PURPOSE: To obtain benzenesulfonamide derivatives that are 5-lipoxygenase inhibitors useful as pharmaceutical compositions for treating various infectious and allergic diseases by allowing specified benzenesulfonamides having leaving groups to react with aromatic compounds having nucleophilic groups.  
     CONSTITUTION: A compd. of the formula I [wherein R 1  is 1-4C alkyl or 3-4C alkenyl, etc.; R 2  and R 3  in together form the formula A 2 -X 2 -A 3  (in which each of A 2  and A 3  is 1-3C alkylene; X 2  is O, S or SO, etc.); X 1  is O, S or imino; Ar is (substd.) phenylene] is bonded with a benzenesulfonamide deriv. of the formula II [wherein Z is a leaving group; R 4  is 1-4C alkyl or (substd.) phenyl, etc.; R 5  is H or 1-4C alkyl; R 6  is H, halogen or 1-4C alkyl, etc.; A 1  is a direct bond or 1-3C alkylene]. Thereafter, the protecting group is removed by a conventional method. The obtained compd. is converted into a pharmaceutically acceptable salt, to obtain the objective benzenesulfonamide deriv. expressed by the formula III. The deriv. is a lipoxygenase inhibitor and it is used for treating various infections and/or allergic diseases. 
     COPYRIGHT: (C)1993,JPO